Option chain shows key data for Faraday Copper's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Faraday Copper.

Faraday Copper (OTC:CPPKF) Stock, Option Chain

Faraday Copper Corp is engaged in the acquisition and development of mineral properties. The company is focused on advancing its flagship copper project in Arizona, The Copper Creek project is one of the undeveloped copper projects in North America with open pit and bulk underground mining potential.

FARADAY COPPER CORP by FARADAY COPPER CORP.

Faraday Copper Corp

News

Management

FAST

Fastenal Announces Senior Executive Vice President And Chief Financial Officer Holden Lewis Provided Notice Of His Resignation, Effective On Apr. 16, 2025

Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $184.75, a high estimate of $210.00, and a low estimate of $170.00. Surpassing the previous average price target of $168.86, the current average has increased by 9.41%.
<img src="https://www.benzinga.com/files/images/story/2024/1735304440_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The standing of Masimo among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Raises</td>
<td>Outperform</td>
<td>$194.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$210.00</td>
<td>$180.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$193.00</td>
<td>$171.00</td>
</tr>
<tr>
<td>Rick Wise</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$190.00</td>
<td>$170.00</td>
</tr>
<tr>
<td>Jayson Bedford</td>
<td>Raymond James</td>
<td>Announces</td>
<td>Outperform</td>
<td>$170.00</td>
<td>-</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$171.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Jason Bednar</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$180.00</td>
<td>$165.00</td>
</tr>
<tr>
<td>Marie Thibault</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$170.00</td>
<td>$166.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Masimo. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Masimo compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Masimo's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Masimo's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/MASI/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Masimo analyst ratings.</a>
<h2>Discovering Masimo: A Closer Look</h2>
Masimo Corp is a global technology company. The company's segment includes healthcare and non-healthcare. The healthcare business segment is a key revenue driver, develops, manufactures, and markets a variety of noninvasive patient monitoring technologies, hospital automation and connectivity solutions, remote monitoring devices and consumer health products. Its non-healthcare segment includes consumer audio business develops, manufactures, markets sells and licenses premium and luxury audio sound products and related integration technologies.
<h3>Masimo's Financial Performance</h3>
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: Over the 3 months period, Masimo showcased positive performance, achieving a revenue growth rate of 5.37% as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Masimo's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 1.94%, the company may face hurdles in effective cost management.
Return on Equity (ROE): Masimo's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 0.69%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Masimo's ROA falls below industry averages, indicating challenges in efficiently utilizing assets. With an ROA of 0.33%, the company may face hurdles in generating optimal returns from its assets.
Debt Management: Masimo's debt-to-equity ratio is notably higher than the industry average. With a ratio of 0.59, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by predicting how much money a company will make in the future, usually the upcoming five years, and how risky or predictable that company's revenue streams are.
Analysts attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish their ratings on stocks. Analysts typically rate each stock once per quarter or whenever the company has a major update.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

MASI

What Analysts Are Saying About Masimo Stock

KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) has been analyzed by 11 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">3</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Insights from analysts' 12-month price targets are revealed, presenting an average target of $33.45, a high estimate of $41.00, and a low estimate of $30.00. This current average represents a 0.89% decrease from the previous average price target of $33.75. 
<img src="https://www.benzinga.com/files/images/story/2024/1735304428_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of KinderCare Learning among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$35.00</td>
<td>$41.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$31.00</td>
<td>$34.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$30.00</td>
<td>$30.00</td>
</tr>
<tr>
<td>Faiza Alwy</td>
<td>Deutsche Bank</td>
<td>Announces</td>
<td>Hold</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Announces</td>
<td>Buy</td>
<td>$36.00</td>
<td>-</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Announces</td>
<td>Equal-Weight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Announces</td>
<td>Buy</td>
<td>$41.00</td>
<td>-</td>
</tr>
<tr>
<td>Manav Patnaik</td>
<td>Barclays</td>
<td>Announces</td>
<td>Overweight</td>
<td>$38.00</td>
<td>-</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Overweight</td>
<td>$31.00</td>
<td>-</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Announces</td>
<td>Outperform</td>
<td>$34.00</td>
<td>-</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to KinderCare Learning. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of KinderCare Learning compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of KinderCare Learning's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into KinderCare Learning's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/KLC/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on KinderCare Learning analyst ratings.</a>
<h2>Get to Know KinderCare Learning Better</h2>
KinderCare Learning Companies Inc is a private provider of early childhood education and care services (ECE) in the United States. It serves children ranging from 6 weeks to 12 years of age across its market- leading footprint of around 1,480 early childhood education centers with a capacity of more than 194,000 children and contracts for more than 650 before- and after-school sites located in 40 states and the District of Columbia. Its three go-to-market channels are KinderCare Learning Centers, KinderCare Education at Work, and Champions.
<h3>Financial Insights: KinderCare Learning</h3>
Market Capitalization Analysis: Falling below industry benchmarks, the company's market capitalization reflects a reduced size compared to peers. This positioning may be influenced by factors such as growth expectations or operational capacity.
Revenue Growth: KinderCare Learning's remarkable performance in 3 months is evident. As of 30 September, 2024, the company achieved an impressive revenue growth rate of 7.53%. This signifies a substantial increase in the company's top-line earnings. When compared to others in the Consumer Discretionary sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: KinderCare Learning's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.08% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): KinderCare Learning's ROE stands out, surpassing industry averages. With an impressive ROE of 5.9%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): KinderCare Learning's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.38%, the company showcases efficient use of assets and strong financial health.
Debt Management: With a high debt-to-equity ratio of 12.62, KinderCare Learning faces challenges in effectively managing its debt levels, indicating potential financial strain.
<h2>What Are Analyst Ratings?</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Forecasting The Future: 11 Analyst Projections For KinderCare Learning

In the latest quarter, 10 analysts provided ratings for Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>), showcasing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">2</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have set 12-month price targets for Bright Horizons Family, revealing an average target of $136.1, a high estimate of $162.00, and a low estimate of $102.00. Witnessing a positive shift, the current average has risen by 2.33% from the previous average price target of $133.00.
<img src="https://www.benzinga.com/files/images/story/2024/1735304416_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Bright Horizons Family. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$142.00</td>
<td>$162.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Lowers</td>
<td>Underweight</td>
<td>$102.00</td>
<td>$108.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$140.00</td>
<td>$140.00</td>
</tr>
<tr>
<td>Jeffrey Silber</td>
<td>BMO Capital</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$125.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$148.00</td>
<td>$145.00</td>
</tr>
<tr>
<td>George Tong</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$162.00</td>
<td>$142.00</td>
</tr>
<tr>
<td>Andrew Steinerman</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$149.00</td>
<td>$137.00</td>
</tr>
<tr>
<td>Toni Kaplan</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Underweight</td>
<td>$108.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Jeffrey Meuler</td>
<td>Baird</td>
<td>Raises</td>
<td>Neutral</td>
<td>$140.00</td>
<td>$131.00</td>
</tr>
<tr>
<td>Joshua Chan</td>
<td>UBS</td>
<td>Raises</td>
<td>Neutral</td>
<td>$145.00</td>
<td>$128.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Bright Horizons Family. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Unveiling insights, analysts deliver qualitative insights into stock performance, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Bright Horizons Family compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Bright Horizons Family's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Bright Horizons Family's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/BFAM/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Bright Horizons Family analyst ratings.</a>
<h2>About Bright Horizons Family</h2>
Bright Horizons Family Solutions Inc provides education and care solutions designed to help employers support their employees in managing their work/life balance. The company has three business segments: full-service center-based child care, backup care, and educational advisory services. The vast majority of the company's revenue is generated by full-service center-based child care, which includes traditional center-based child care and early education services. Other services provided by the company include in-home child and elder care, tuition assistance, and education consulting. The company earns more than half of its revenue in North America.
<h3>Bright Horizons Family's Economic Impact: An Analysis</h3>
Market Capitalization Analysis: Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.
Revenue Growth: Bright Horizons Family's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately 11.35%. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 7.64%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Bright Horizons Family's ROE excels beyond industry benchmarks, reaching 4.09%. This signifies robust financial management and efficient use of shareholder equity capital.
Return on Assets (ROA): The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of 1.42%, the company showcases effective utilization of assets.
Debt Management: Bright Horizons Family's debt-to-equity ratio is notably higher than the industry average. With a ratio of 1.32, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>Analyst Ratings: Simplified</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BFAM

Beyond The Numbers: 10 Analysts Discuss Bright Horizons Family Stock

Takeda Pharmaceutical Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TAK#NYSE">TAK</a>) announced on Friday that the Japanese Ministry of Health, Labour and Welfare has approved HYQVIA (Immune Globulin Infusion 10% with Recombinant Human Hyaluronidase) for the treatment of patients <a target="_blank" href="https://www.benzinga.com/pressreleases/24/12/b42697319/takeda-announces-approval-of-hyqvia-10-s-c-subcutaneous-injection-set-in-japan-for-patients-with-a" rel="noreferrer noopener">with agammaglobulinemia or hypogammaglobulinemia.</a>
These conditions, characterized by low or absent antibody levels, result in an increased risk of serious infections. This approval introduces the first and only facilitated subcutaneous immunoglobulin (fSCIG) therapy in Japan, offering patients a new treatment option.
HYQVIA combines subcutaneous immunoglobulin (10%) with recombinant human hyaluronidase (rHuPH20), which facilitates larger volume infusions by increasing the dispersion and absorption of immunoglobulin in subcutaneous tissue.
Also Read: <a target="_blank" href="https://www.benzinga.com/24/12/42696705/bitcoin-ethereum-dogecoin-retreat-after-christmas-surge-top-analyst-highlights-what-btc-needs-to-do-to-invalidate-bearish-outlook" rel="noreferrer noopener">Bitcoin, Ethereum, Dogecoin Pull Back After Christmas Rally: Top Analyst Reveals What Happens Next After BTC Fails To Record Daily Close Above $100K</a>
This allows for less frequent dosing, with treatments every 3 to 4 weeks, compared to weekly or bi-weekly infusions with other subcutaneous immunoglobulin treatments.
This flexibility eliminates the need for venous access, offering patients greater convenience.
The approval was based on data from two Phase 3 clinical trials conducted in Japan and North America.
These studies showed that HYQVIA maintained stable IgG levels comparable to intravenous or other subcutaneous immunoglobulin treatments, with manageable side effects such as mild fever and injection site reactions.
Takeda's commitment to offering differentiated immunoglobulin therapies is further demonstrated by this approval, which expands its portfolio in Japan.
The company also continues to invest in local manufacturing to meet the growing demand for plasma-derived therapies as education and diagnosis of immunodeficiencies improve.
Price Action: TAK shares are trading higher by 1.07% to $13.28&nbsp;premarket at last check Friday.
Read Next:&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42690488/are-donald-trumps-ambitious-bitcoin-goals-feasible" target="_blank" rel="noreferrer noopener">Are Donald Trump's Ambitious Bitcoin Goals Feasible?</a></li>
</ul>

Asia

Equities

Markets

Movers

General

Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency

UBS analyst Jay Sole reiterates On Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ONON#NYSE">ONON</a>) with a Buy and maintains $63 price target.

Price Target

Reiteration

ONON

UBS Reiterates Buy on On Holding, Maintains $63 Price Target

B of A Securities analyst Sachin Salgaonkar maintains MakeMyTrip (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MMYT#NASDAQ">MMYT</a>) with a Buy and raises the price target from $119 to $130.

MMYT

B of A Securities Maintains Buy on MakeMyTrip, Raises Price Target to $130

EVject first came into focus after EV giant Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) sued it over the safety of its &#8216;breakaway&#8217; <a href="https://www.benzinga.com/news/24/07/39951183/tesla-supercharger-network-growth-slows-down-in-q2-after-exit-of-rebecca-tinucci-and-other-employees" target="_blank" rel="noreferrer noopener">charging connector for EV drivers.</a>
EVject's charging connector allows drivers to disconnect from EV chargers and drive away in emergencies without stepping out of the vehicle. Tesla filed a lawsuit against EVject earlier this year alleging that their breakaway connectors are "dangerous" and pose a high safety risk.
Inspiration Behind The Breakaway Connector: EVject founder Kreg Peeler in an interview detailed the inspiration behind the connector. 
&#8220;We came into existence because we kept hearing about this problem where it&#8217;s not just Teslas, but all EVs. Any electric vehicle plugged in at a public charger is disabled while charging,&#8221; Peeler said. 
Tesla&#8217;s Lawsuit: The company developed its breakaway connector device and shipped all its preorders in February earlier this year before it received a notice from Tesla. Tesla subsequently requested a few EVject connectors to test and said it has no over-temperature protection and may overheat when charging.
Peeler subsequently took to X noting his differences with the testing and Tesla CEO Elon Musk assured in a post on X that he &#8220;will investigate&#8221; the issue. 
Tesla later reached out to Peeler and EVject agreed to have a thermal sensor included in the product as a protective measure in case of overheating and the EV maker subsequently dropped the lawsuit. 
Boon In Disguise?: As per Peeler, it would cost EVJect $30,000 to get the connectors shipped to customers back and then retrofit them with thermal sensors before sending them back out.
&#8220;It&#8217;s about $30,000. But overall, we think the market exposure and the awareness we got out of it was probably worth that,&#8221; Peeler said.
The lawsuit threw EVject into the spotlight, with several players showing interest in the company&#8217;s connector device, including German automaker Volkswagen.
The company is now looking forward to showcasing a few of its products to Volkswagen in March. 
EVject has shipped 3,500 of its breakaway connectors to date. While the company is making a profit per device, it is yet to be profitable as a corporation. The company is now looking to scale in terms of volume and has also got ideas for new products to develop when they have enough cash flow.
&#8220;By 2030, we want to have sold millions of units and have the company be worth a billion dollars. So that&#8217;s five years away. Or get acquired somewhere along the way. If Volkswagen or Tesla came in and made us a good offer, we would seriously consider it,&#8221; Peeler said. 
Check out more of Benzinga's Future Of Mobility coverage by&nbsp;<a href="https://www.benzinga.com/topic/mobility" target="_blank" rel="noreferrer noopener">following this link.</a>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/24/12/42668333/tesla-model-x-lucid-gravity-or-rivian-r1s-which-three-row-electric-suv-is-a-better-buy" target="_blank" rel="noreferrer noopener">Tesla Model X, Lucid Gravity Or Rivian R1S: Which Three-Row Electric SUV Is A Better Buy?</a></li>
</ul>
Photo courtesy: EVject

Tech

TSLA

Tesla's Lawsuit Has Startup EVject Looking At A Potential Partnership With Volkswagen

U.S. equity markets could be headed for a correction due to a confluence of factors like the growing divergence from "Magnificent 7" stocks and President-elect Donald Trump's tariff plans, according to market expert Jay Woods.
What Happened: In an interview with <a href="https://www.cnbc.com/video/2024/12/27/market-is-at-the-beginning-of-a-10-percent-correction-says-freedom-capitals-jay-woods.html">CNBC</a>, Woods, chief market strategist at Freedom Capital Markets, cautioned about the possibility of a market correction in the near term.
According to Woods, we could be at the beginning of a 10% correction in the equity markets. Woods noted that these corrections happen roughly once every 18 months.
"We've had a tremendous run, 10% correction is due to happen every 18 months… What we're seeing is just horrible market breadth," Woods said.
Woods added that while the "Magnificent 7" stocks — Apple (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), Google parent Alphabet (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOG#NASDAQ">GOOG</a>) (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GOOGL#NASDAQ">GOOGL</a>), Amazon.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMZN#NASDAQ">AMZN</a>), Nvidia (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), Meta Platforms (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/META#NASDAQ">META</a>) and Tesla (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) — have done well, the divergence in their performance and that of the overall market is "getting a little bit too rich" for him.
See Also: <a href="https://www.benzinga.com/24/12/42696614/cathie-wood-takes-profit-on-hot-ai-stock-palantir-again-continues-to-sell-block-shares-amid-bitcoin-buzz">Cathie Wood Takes Profit On Hot AI Stock Palantir Again, Continues To Sell Block Shares Amid Bitcoin Buzz</a>
"Once we get to the new quarter, we're going to have some headwinds to deal with. We may see some of those Mag 7 names give back a little bit. I don't think the rotation will keep us from having a 10% correction."
"It's not going to be fun," he quipped.
Woods also pointed to uncertainty due to Trump's tariff plans as a possible headwind that could have an impact on the markets.
Elon Musk and Vivek Ramaswamy-led Department of Government Efficiency's (DOGE) plans to cut down federal spending could also result in an uptick in unemployment, said Woods.
Why It Matters: The potential for a market correction has been echoed by other financial experts.
Brian Arcese&nbsp;from&nbsp;Foord Asset Management&nbsp;has also <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42133820/potential-healthy-correction-for-an-expensive-market-looms-as-us-economic-growth-and-earnings-slow-says-asset-manager-sp-500-nasdaq-futures-trade-lower-in-premarket">raised concerns</a> about the slowing U.S. economic growth and corporate earnings, which could trigger a correction if they continue to decelerate. Arcese pointed out that the S&amp;P 500 has been &#8220;expensive for quite a while,&#8221; with a price-to-earnings ratio exceeding 27.
Additionally,&nbsp;Jeremy Siegel, professor emeritus at the University of Pennsylvania's Wharton School, described a recent stock market downturn as a <a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42570219/whartons-jeremy-siegel-calls-stock-sell-off-a-healthy-reality-check-market-was-overly-optimistic">&#8220;healthy&#8221; reaction</a> to the Federal Reserve&#8217;s cautious approach to future interest rate cuts.
The Fed&#8217;s decision to lower interest rates by a quarter percentage point led to declines across major Wall Street indexes, as investors had anticipated more aggressive rate reductions.
Billionaire investor&nbsp;David Einhorn <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/11/42087680/billionaire-investor-david-einhorn-calls-it-most-expensive-market-of-all-time-as-sp-500-gains-4-since-trumps-win-really-really-pricey">characterized the market as &#8220;really, really, really pricey,&#8221;</a> noting that the Shiller cyclically adjusted price-to-earnings ratio is at one of the highest levels in a century.
Despite these high valuations, Einhorn clarified that this does not make him bearish, as asset prices can remain mispriced for extended periods.
Price Action: According to <a href="http://pro.benzinga.com">Benzinga Pro</a>, as of Friday&#8217;s pre-market session, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>), which mirrors the S&amp;P 500, has gained 1.68% over the past five days. Similarly, the Invesco QQQ Trust (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>), which tracks the Nasdaq-100 Index, has risen by 1.65% during the same period.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42682230/tech-bull-predicts-26-upside-for-apple-stock-sees-golden-era-of-growth-for-cupertino-due-to-multi-year-ai-driven-iphone-upgrade-cycle">Tech Bull Predicts 26% Upside For Apple Stock, Sees &#8216;Golden Era Of Growth&#8217; For Cupertino Due To Multi-Year AI-Driven iPhone Upgrade Cycle</a></li>
</ul>
Photo courtesy: Shutterstock

Analyst Color

AAPL

AMZN

GOOG

GOOGL

MSFT

NVDA

US Stocks Likely Headed For 10% Correction, Says Top Strategist, Points Out 'Horrible Market Breadth:' Trump's Tariff Plans, Musk Co-Led DOGE Could Be Partially To Blame For Decline

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a<a href="https://www.benzinga.com/yield-investments"> high dividend payout</a>.
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer discretionary sector.
<h3 class="wp-block-heading">Guess?, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GES#NYSE">GES</a>)</h3>
<ul>
<li>Dividend Yield: 8.63%</li>
<li>Small Cap Consumer Research analyst Eric Beder reiterated a Buy rating with a price target of $23 on Dec. 18. This analyst has an accuracy rate of 63%.</li>
<li>Telsey Advisory Group analyst Dana Telsey maintained a Market Perform rating and cut the price target from $21 to $18 on Oct. 27. This analyst has an accuracy rate of 61%.</li>
<li>Recent News: On Nov. 26, Guess? reported a year-over-year decrease in third-quarter adjusted EPS results.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1">latest GES news</a>. </li>
</ul>
<figure class="wp-block-image is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img decoding="async" src="blob:https://editorial.benzinga.com/a966e0da-d6d8-4556-8a69-68ba12052b66" alt="" style="width:651px;height:auto" /></a></figure>
<h3 class="wp-block-heading">Kohl&#8217;s Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KSS#NYSE">KSS</a>)</h3>
<ul>
<li>Dividend Yield: 13.47%</li>
<li>Guggenheim analyst Robert Drbul downgraded the stock from Buy to Neutral on Dec. 2. This analyst has an accuracy rate of 66%.</li>
<li>Citigroup analyst Paul Lejuez maintained a Neutral rating and cut the price target from $18 to $14 on Nov. 27. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On Nov. 27, Kohl&#8217;s reported worse-than-expected third-quarter EPS and sales, cut its FY24 EPS guidance, and projected a net sales decrease of 7%-8%.</li>
<li>Benzinga Pro's real-time newsfeed alerted to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1">latest KSS news</a> </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="896" height="837" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074455/image-219.png" alt="" class="wp-image-709175" style="width:587px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074455/image-219.png 896w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074455/image-219-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074455/image-219-768x717.png 768w" sizes="(max-width: 896px) 100vw, 896px" /></a></figure>
<h3 class="wp-block-heading">Bloomin&#8217; Brands, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BLMN#NASDAQ">BLMN</a>)</h3>
<ul>
<li>Dividend Yield: 7.73%</li>
<li>JP Morgan analyst John Ivankoe maintained a Neutral rating and slashed the price target from $19 to $14 on Nov. 12. This analyst has an accuracy rate of 75%.</li>
<li>Raymond James analyst Brian Vaccaro downgraded the stock from Outperform to Market Perform on Nov. 11. This analyst has an accuracy rate of 81%.</li>
<li>Recent News: On Nov. 8, the company reported third-quarter adjusted earnings per share of 21 cents, beating the street view of 20 cents. Quarterly revenues of $1.038 billion (down 3.8%) missed the analyst consensus of $1.042 billion.</li>
<li>Benzinga Pro&#8217;s charting tool helped identify the <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1">trend in BLMN stock</a>. </li>
</ul>
<figure class="wp-block-image size-full is-resized"><a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent122724&amp;t=be2bearmibe3na1"><img loading="lazy" decoding="async" width="912" height="850" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074537/image-220.png" alt="" class="wp-image-709176" style="width:670px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074537/image-220.png 912w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074537/image-220-300x280.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/27074537/image-220-768x716.png 768w" sizes="(max-width: 912px) 100vw, 912px" /></a></figure>
<figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"> 
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="How to Find Dividend Stocks: Scan, Analyze, and Capture with Benzinga Pro" width="500" height="281" src="https://www.youtube.com/embed/pVF0O2lsEH4?start=1&#038;feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
</figure>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/24/12/42697989/dow-edges-higher-in-thin-holiday-trading-fear-declines-among-us-investors-but-fear-greed-index-remains-in-fear-zone">Dow Edges Higher In Thin Holiday Trading As Tesla, Apple Surge: Investor Sentiment Improves, But Greed Index Remains In &#8216;Fear&#8217; Zone</a></li>
</ul>

Pre-Market Outlook

Trading Ideas

BLMN

Wall Street's Most Accurate Analysts Give Their Take On 3 Consumer Stocks With Over 7% Dividend Yields

Dogecoin's (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>) impressive performance over the past week has sparked bullish sentiment among traders, with some expecting a continuation of <a href="https://www.benzinga.com/money/dogecoin-doge-price-prediction">its upward trend</a>.
<figure class="wp-block-table"> 
<table>
<tbody>
<tr>
<td>Cryptocurrency</td>
<td>Price&nbsp;&nbsp;&nbsp;</td>
<td>Market Cap</td>
<td>24-Hour Trend</td>
<td>7-Day Trend</td>
</tr>
<tr>
<td>Dogecoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/doge/usd">DOGE</a>)</td>
<td>&nbsp;$0.3207</td>
<td>$47.3 billion</td>
<td>+1.4%&nbsp;</td>
<td>&nbsp;+19%</td>
</tr>
<tr>
<td>Shiba Inu (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/shib/usd">SHIB</a>)</td>
<td>&nbsp;$0.00002229</td>
<td>$13.1 billion</td>
<td>+2.9%&nbsp;</td>
<td>+19.2%&nbsp;</td>
</tr>
<tr>
<td>Pepe (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/">PEPE</a>)</td>
<td>&nbsp;$0.00001806&nbsp;</td>
<td>$7.6 billion</td>
<td>+4.3%&nbsp;</td>
<td>+23.9%&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Trader Notes: Ali Martinez, a crypto chart analyst, flagged a &#8220;buy signal&#8221; on Dogecoin's 4-hour chart, anticipating a price rebound.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The TD Sequential presents a buy signal on the <a href="https://twitter.com/hashtag/Dogecoin?src=hash&amp;ref_src=twsrc%5Etfw">#Dogecoin</a> <a href="https://twitter.com/search?q=%24DOGE&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$DOGE</a> 4-hour chart, anticipating a price rebound! <a href="https://t.co/ffwthCQL5B">pic.twitter.com/ffwthCQL5B</a>
&mdash; Ali (@ali_charts) <a href="https://twitter.com/ali_charts/status/1872564616804643278?ref_src=twsrc%5Etfw">December 27, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Similarly, Trader Tardigrade <a href="https://x.com/TATrader_Alan/status/1872573261789487222">pointed</a> to a &#8220;Spinning Top&#8221; candlestick pattern on the DOGE weekly chart, typically signaling a potential bottom. Coupled with RSI levels approaching support, these factors suggest Dogecoin may be gearing up for another rally.
Statistics: Martinez also <a href="https://x.com/ali_charts/status/1872597229552459783">highlighted</a> significant whale activity, with over 90 million DOGE purchased in the past 48 hours. This level of accumulation often indicates expectations of a price rebound or a major market development.
Data from Coinglass reveals $6.7 million in DOGE liquidations over the last 24 hours, including $4.7 million in long positions. The sustained open interest of $2 billion—despite recent declines—reflects growing optimism around Dogecoin's future price trajectory.
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/markets/cryptocurrency/24/12/42682141/dogecoin-price-down-4-what-is-going-on">Dogecoin Price Down 4%: What Is Going On?</a></li>
</ul>
Image: Shutterstock

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

$DOGE

$PEPE

$SHIB

Dogecoin Jumps 19% In Christmas Week Rally: What Is Going On?

Goldman Sachs analyst George Tong maintains KinderCare Learning (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KLC#NYSE">KLC</a>) with a Buy and lowers the price target from $41 to $35.

Goldman Sachs Maintains Buy on KinderCare Learning, Lowers Price Target to $35

Goldman Sachs analyst George Tong maintains Bright Horizons Family (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BFAM#NYSE">BFAM</a>) with a Buy and lowers the price target from $162 to $142.

Goldman Sachs Maintains Buy on Bright Horizons Family, Lowers Price Target to $142

Baird analyst Joe Vruwink initiates coverage on ServiceTitan (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTAN#NASDAQ">TTAN</a>) with a Outperform rating and announces Price Target of $117.

Initiation

TTAN

Baird Initiates Coverage On ServiceTitan with Outperform Rating, Announces Price Target of $117

Legal

BNTX

BioNTech Entered Settlement Agreement With NIH for $791.5M Over COVID-19 Vaccine Royalties (2020-2023)

Raymond James analyst Jayson Bedford maintains Masimo (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MASI#NASDAQ">MASI</a>) with a Outperform and raises the price target from $170 to $194.

Raymond James Maintains Outperform on Masimo, Raises Price Target to $194

For the quarter and year ended September 28, 2024, the Company recognized an impairment loss of $30.4 million related to inventory damaged or destroyed by Hurricane Helene.&nbsp;
Additionally, the Company also recognized a property and equipment impairment loss of $4.5 million for the quarter and year ended September 28, 2024.

IMKTA

Ingles Markets Reports Q4 Net Sales Of $1.4B Lower Than $1.58B, Diluted Losses Per Share Was $0.08

U.S. stock futures tumbled on Friday in premarket hours after a mixed Thursday. All four index futures slipped in trade.
While the S&amp;P 500 index is on its way to registering a robust 20% plus return for the second consecutive year in 2024 it ended lower on the second day of the Santa rally after advancing 1.1% on Christmas Eve. Analysts say that the full &#8216;Santa Claus Rally&#8217; has never been lower.
The 10-year and two-year Treasury notes yielded 4.61% and 4.33%, respectively. The probability of having no change in the interest rates for the upcoming Jan. 31, 2025 decision was at 89.3%, down from 91.4% a week ago, according <a href="https://www.cmegroup.com/markets/interest-rates/cme-fedwatch-tool.html">to</a> CME Group&#8217;s FedWatch tool.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Futures</td>
<td>Change (+/-)</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>-0.42%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.43%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>-0.41%</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>-0.43%</td>
</tr>
</tbody>
</table>
</figure>
In premarket trading on Friday, the SPDR S&amp;P 500 ETF Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) was up 0.04% to $601.34 and the Invesco QQQ Trust ETF (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) fell 0.36% to $527.70, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro data</a>.
Cues From The Last Session
U.S. stock markets closed mixed on Thursday, following a Christmas break. The Dow Jones Industrial Average edged <a href="https://www.benzinga.com/24/12/42697989/dow-edges-higher-in-thin-holiday-trading-fear-declines-among-us-investors-but-fear-greed-index-remains-in-fear-zone">higher</a>, while the S&amp;P 500 and Nasdaq Composite dipped slightly.
Month-to-date performance varied across indices. The Nasdaq significantly outperformed, driven by strong gains in Tesla Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) and Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), while the Dow Jones experienced a decline of around 3.5%. The S&amp;P 500 saw a modest gain of 0.1%.
Economic data released on Thursday showed a slight decrease in initial jobless claims, coming in below market expectations. This suggests a continued strong labor market.
Sector performance was mixed. Healthcare, financial, and real estate sectors led gains, while consumer discretionary and communication services sectors underperformed.
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Index</td>
<td>Performance (+/-)</td>
<td>Value</td>
</tr>
<tr>
<td>Nasdaq Composite</td>
<td>-0.05%</td>
<td>20,020.36</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>-0.04%</td>
<td>6,037.59 </td>
</tr>
<tr>
<td>Dow Jones</td>
<td>0.07%</td>
<td>43,325.80 </td>
</tr>
<tr>
<td>Russell 2000</td>
<td>0.90%</td>
<td>2,280.19 </td>
</tr>
</tbody>
</table>
</figure>
Insights From Analysts
According to the chief market strategist at Carson Research, Ryan Detrick, the final six days of the &#8216;Santa Claus Rally&#8217; has been higher five out of seven, with two small losses. But even these six days have been higher by 1.7% on average.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 gained more than 1% on the first day of the Santa Claus Rally (SCR). Now what? Full SCR period has never been lower, up 7 out of 7. Final 6 days? Higher 5 of 7, with two small losses and up 1.7% on avg. &#x1f385;&#x1f4aa; <a href="https://t.co/dwCKraVxAA">pic.twitter.com/dwCKraVxAA</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1872323859334238441?ref_src=twsrc%5Etfw">December 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Mapping the data from 1950, Detrick summarized that the S&amp;P 500 has had a 20% plus return 22 times and a negative return annual return or 21 times in total.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">We are about to have more years, since 1950, that saw stocks gain 20% (22) than had a negative year (21). Impress your friends at the New Year&#39;s Eve party with that stat. <a href="https://t.co/LDn0m6uBf6">pic.twitter.com/LDn0m6uBf6</a>
&mdash; Ryan Detrick, CMT (@RyanDetrick) <a href="https://twitter.com/RyanDetrick/status/1872422872427470946?ref_src=twsrc%5Etfw">December 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
According to Charlie Bilello, the chief market strategist at Creative Planning the S&amp;P 500&#8217;s 57 all-time highs in 2024 was the fifth highest in its history.
<figure class="wp-block-embed is-type-rich is-provider-twitter wp-block-embed-twitter"> 
<div class="wp-block-embed__wrapper">
<blockquote class="twitter-tweet" data-width="500" data-dnt="true">The S&amp;P 500 has hit 57 all-time highs so far in 2024, the 5th most of any year in history. <a href="https://twitter.com/search?q=%24SPX&amp;src=ctag&amp;ref_src=twsrc%5Etfw">$SPX</a> Video: <a href="https://t.co/a2jVufnOfZ">https://t.co/a2jVufnOfZ</a> <a href="https://t.co/3xe6W8ub5b">pic.twitter.com/3xe6W8ub5b</a>
&mdash; Charlie Bilello (@charliebilello) <a href="https://twitter.com/charliebilello/status/1872330869236539691?ref_src=twsrc%5Etfw">December 26, 2024</a></blockquote>
<script async src="https://platform.twitter.com/widgets.js" charset="utf-8"></script></div>
</figure>
Louis Navellier of Navellier &amp; Associates in his daily market commentary said, &#8220;The Fed may be turning its attention to inflation, according to Fed Chairman Jerome Powell's comments, but if continuing unemployment claims continue to rise, it will likely get the Fed's attention and encourage more key interest rate cuts.&#8221;
&#8220;Continuing unemployment claims rose to 1.91 million in the latest week, which represents the highest level in more than three years. New unemployment claims came in at 219,000, which was a bit lower than the four-week moving average of 226,500,&#8221; he added.
See Also:&nbsp;<a href="https://www.benzinga.com/money/how-to-trade-futures">How To Trade Futures</a>
Upcoming Economic Data
Only a few data points remain to be released in this truncated week that will help investors determine the future course of action.
<ul>
<li>On Friday, November&#8217;s data for the advanced U.S. trade balance in goods, advanced retail inventories, and advanced wholesale inventories will be announced at 8:30 a.m., ET.</li>
</ul>
Stocks In Focus:
<ul>
<li>Viracta Therapeutics Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) was down 21.90% in premarket after it said that the company board has initiated a process to explore a broad range of strategic alternatives to close its ongoing pivotal Phase 2 clinical trial of Nana-val in Relapsed/Refractory EBV + Lymphomas.</li>
</ul>
<ul>
<li>Evaxion Biotech A/S (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EVAX#NASDAQ">EVAX</a>) was up 67.85% as it applied for a patent for vaccines targeting Neisseria gonorrhoeae.</li>
</ul>
<ul>
<li>Grid Dynamics Holdings Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GDYN#NASDAQ">GDYN</a>) was up 7.31% as it will replace Revelyst Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GEAR#NYSE">GEAR</a>) in the S&amp;P SmallCap 600 effective before the opening bell on Thursday, Jan. 2.</li>
</ul>
<ul>
<li>Sealsq Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) was up 6.28% in premarket after it regained compliance with Nasdaq's minimum bid price requirement, securing its position on the stock market.</li>
</ul>
<ul>
<li>Rigetti Computing Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGTI#NASDAQ">RGTI</a>) was up 8.16% in premarket after a 36% jump on Thursday. It launched its 84-qubit Ankaa-3 system, a quantum computer featuring an extensive hardware redesign that enables superior performance on Dec. 23 and the stock has been up by 543.33% month-to-date.</li>
</ul>
<ul>
<li>Rezolve AI Ltd (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RZLV#NASDAQ">RZLV</a>) was up 10.61% in premarket and it has surged by 109.05% over the last month. The company announced the pricing of its $15 million registered offering last week.</li>
</ul>
Commodities, Gold And Global Equity Markets:
Crude oil futures were higher in the early New York session by 0.46% to hover around $69.94 per barrel.
The gold spot index was down by 0.48% to $2,641.11 per ounce. The Dollar Index was up 0.01% to 108.138 level.
Asian markets were mixed on Friday, as Hong Kong&#8217;s Hang Seng, China&#8217;s CSI 300, and South Korea&#8217;s Kospi index declined. Whereas, Japan&#8217;s Nikkei 225, Australia&#8217;s ASX 200, and India&#8217;s S&amp;P BSE Sensex index rose. Most European markets traded higher.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42678014/top-7-blue-chip-stocks-with-the-best-return-potential-going-into-2025">S&amp;P 500 Hits 57 All-Time Highs In Record-Breaking 2024: Magnificent 7 Drive 30% Of Nasdaq&#8217;s Surge</a></li>
</ul>
Photo courtesy: Wikimedia

Futures

Economics

Federal Reserve

EVAX

GDYN

GEAR

LAES

RGTI

RZLV

TSX:RSLV

VIRX

US Stocks To Open Lower As Index Future Decline: Analysts Remain Upbeat About Santa Rally

BioNTech Entered $467M Settlement Agreement With University Of Pennsylvania; Will Retain License Rights Under Some Penn Patents

Rodman &amp; Renshaw downgrades Viracta Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VIRX#NASDAQ">VIRX</a>) from Buy to Neutral and lowers the price target from $3.5 to $0.25.

Downgrades

Rodman & Renshaw Downgrades Viracta Therapeutics to Neutral, Lowers Price Target to $0.25

Faraday Copper Q4 GAAP EPS of -C$0.03

CPPKF

Press Releases

Faraday Copper Intersects 20.07 m at 1.20% Copper within 100.29 m at 0.42% Copper in the American Eagle Area

Faraday Copper Intersects 0.62% Copper Over 29.08 Metres Within 190.25 Metres at 0.23% Copper Near Surface at the Prada Breccia in the American Eagle Area

Why Gold and Copper Mining Markets Are Projected to Increase in Coming Years as Demand Jumps

Earnings

Faraday Copper Reports Second Quarter 2024 Financial Results

Faraday Copper Intersects 1.01% Copper Over 117.90 Metres within 269.65 Metres at 0.64% Copper, Discovering the High-Grade Mineralized Banjo Breccia in the American Eagle Area

Faraday Copper Intersects 1.12% Copper over 117.83 Metres within 259.98 Metres at 0.68% Copper at the Recently Discovered Banjo Breccia in the American Eagle Area

Small Cap

NEMESIA S.À R.L. COMPLETES CORPORATE RESTRUCTURING AND ACQUIRES SHARES AND WARRANTS OF FARADAY COPPER CORP.

Faraday Copper Intersects 1.31% Copper over 22.65 Metres within 50.20 Metres at 0.74% Copper Near Surface at the Banjo Breccia

Faraday Copper Reports Third Quarter 2024 Financial Results

Faraday Copper Intersects 23.25 Metres at 1.58% Copper Within 57.73 Metres at 0.85% Copper in the Rum Area

Comments

Faraday Copper

Faraday Copper (CPPKF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga